Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT ID: NCT03001622

Last Updated: 2017-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-31
• Study Completion Date: 2017-07-31

Brief Summary

The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints (e.g., Hidradenitis Suppurativa Clinical Response (HiSCR), Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) for disease, VAS for pain, Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA), Modified Sartorius Score (mSS)).

Conditions

Hidradenitis Suppurativa

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IFX-1

Group Type: OTHER

IFX-1

Intervention Type: BIOLOGICAL

chimeric, monoclonal antibody

Interventions

IFX-1

chimeric, monoclonal antibody

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients ≥ 18 years old

2. Written informed consent

3. Diagnosis of HS for at least 1 year

4. Hidradenitis suppurativa (HS) lesions in at least 2 distinct anatomic areas, one of which is Hurley Stage II or III

5. Total AN (abscesses and nodules) count ≥3

6. Patients with either primary or secondary failure of biological treatment or are not eligible for treatment with other biologicals

7. Failure of previous antimicrobial treatments

Exclusion Criteria

1. Body weight above 150 kg or body weight below 60 kg

2. Has a draining fistula count of greater than 30 at baseline

3. Surgical management planned within the next 24 weeks

4. Occurrence of a flare-up of HS leading to intravenous antimicrobial treatment within the last 14 days

5. Any other disease and condition that is likely to interfere with evaluation of study product, outcome assessment or satisfactory conduct of the study

1. Active infection

2. Severe congestive heart failure (i.e., New York Heart Association (NYHA) Class IV)

3. Depression

4. History of systemic lupus erythematosus or rheumatoid arthritis

5. Any immunodeficiency disease

6. Active hematological or solid malignant tumor

7. Patients must not have had any other active skin disease or condition (e.g., bacterial, fungal, or viral infection) that may have interfered with assessment of HS.

6. One of the following abnormal laboratory results

1. White blood cell count < 2,500/mm3

2. Neutrophil count < 1000/mm3

3. Serum Creatinine > 3 x Upper Normal Limit (UNL)

4. Total Bilirubin > 2 x UNL

5. Alanine-Aminotransferase (ALAT) > 2 x UNL

6. Positive screening test for Hepatitis B, Hepatitis C, or HIV 1/2

7. Prior administration of any biological compound in the last 3 months

8. Intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1 mg/kg for the last three weeks;

9. Intake of Immunosuppressive drugs within past 30 days (e.g., cyclosporine, tacrolimus)

1. Pregnant (in women of childbearing potential an urine pregnancy test has to be performed) or breast-feeding women

2. Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial

3. Participation in any interventional clinical trial within the last three months

4. Known intravenous drug abuse

5. Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InflaRx GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

ATTIKON University Hospital

Athens, , Greece

Countries

Greece

References

Prens LM, Ardon CB, van Straalen KR, van der Zee HH, Seelen MAJ, Laman JD, Prens EP, Horvath B, Damman J. No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa. J Invest Dermatol. 2021 Dec;141(12):2966-2969.e1. doi: 10.1016/j.jid.2021.03.037. Epub 2021 Jul 9. No abstract available.

Reference Type: DERIVED

PMID: 34252397 (View on PubMed)

Other Identifiers

IFX-1-P2.3

Identifier Type: -

Identifier Source: org_study_id